NEW YORK (Reuters Health) - On average, men's levels of prostate-specific antigen (PSA) decrease as their body mass index (BMI) rises, a new study shows. PSA is a marker for prostate cancer risk when ...

Hemodilution from increased circulating plasma volumes could explain why obese men with prostate cancer have lower serum PSA levels than non-obese men with the malignancy, according to researchers. A ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

High comorbidity as a predictor of poorer survival and ARPI efficacy in metastatic prostate cancer. Real-world characteristics of long-term survivors with metastatic castration-resistant prostate ...

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

November 18, 2008 (Washington, DC) — The use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is significantly associated with lower levels of prostate-specific antigen (PSA).

Opportunistic prostate cancer screening can lead to overdiagnosis of indolent diseases and invasive procedures. A cohort study suggested that a low baseline PSA level in midlife was associated with a ...

Results challenge view that high testosterone fuels prostate cancer growth ...